Report Highlights

Vitreoretinal disorders at a turning point: Market Overview

The global vitreoretinal disorder market stood at USD 11.4 billion in 2024, sustained by an aging global population, surging rates of diabetes-linked retinopathy, and the commercial dominance of anti-VEGF therapies across North America and Europe. The market has expanded at a consistent mid-single-digit pace over the past decade, anchored by blockbuster biologics — Eylea (aflibercept) and Lucentis (ranibizumab) — that together account for nearly 60% of therapeutic revenues. A structural shift is now underway as the biologic duopoly erodes under biosimilar pressure while next-generation mechanisms, including complement inhibitors, tyrosine kinase inhibitors (TKIs), and gene therapy platforms, are transitioning from late-stage trials to commercial launch, fundamentally redistributing revenue share.

The current moment qualifies as a genuine inflection point for three reasons. First, the FDA approval of Syfovre for geographic atrophy in 2023 opened an entirely new disease indication that had no approved therapy for decades, creating a USD 3 billion addressable opportunity in the U.S. market alone. Second, port delivery systems and extended-release implants — including Genentech's Susvimo — are shifting treatment paradigms away from monthly injections toward six-month dosing intervals, which rewires how ophthalmology practices generate and retain revenue. Third, the entry of gene therapy programs, particularly REGENXBIO's RGX-314 and Adverum Biotechnologies' ADVM-022, into pivotal trials signals that one-time curative options will reach commercialisation before 2030, compressing the long-term addressable market for chronic biologics.

Key forces shaping vitreoretinal disorder growth

Three forces are directly translating into market revenue growth. The first is epidemiological inevitability: diabetic retinopathy affects an estimated 103 million people globally, and the International Diabetes Federation projects this will exceed 160 million by 2045. Every diabetic retinopathy patient represents a multi-year treatment cycle requiring repeated intravitreal injections or surgical intervention, generating high per-patient lifetime value. This dynamic is most acute in Asia Pacific, where diabetes prevalence is rising fastest and healthcare infrastructure is expanding to meet diagnostic and therapeutic demand, making this region the primary volume growth engine for vitreoretinal therapeutics over the forecast period.

The second force is technological differentiation driving premium pricing. Devices such as the Alcon NGENUITY 3D visualization system and Zeiss ARTEVO 800 digital microscope are commanding premium procedure reimbursements in the U.S. and Germany, replacing conventional microscopes across tertiary ophthalmology centres and lifting average selling prices for surgical episodes. The third force is pipeline breadth: over 80 vitreoretinal drug candidates are currently in Phase 2 or Phase 3 development globally, an unprecedented density that guarantees multiple approvals through 2030. Each successful launch creates incremental revenue rather than direct substitution, because the underlying patient population across AMD, diabetic macular edema, and retinal vein occlusion is expanding faster than existing therapies fully address it.

Barriers and risks in the vitreoretinal disorder market

The most immediate and commercially disruptive risk is biosimilar-driven price erosion in the anti-VEGF segment, which generates the majority of current market revenue. Ranibizumab biosimilars from Samsung Bioepis (Byooviz) and Coherus BioSciences (Cimerli) have already penetrated U.S. and European formularies, while aflibercept biosimilars from Biocon and Mylan intensify this dynamic further. This is a structural risk — not cyclical — because patent cliffs do not reverse, and the institutional payer infrastructure in the U.S. and Germany is systematically incentivised to substitution. The net revenue loss to incumbent manufacturers from biosimilar conversion is estimated to reach USD 1.8 billion annually by 2028, compressing segment margins even as overall market volume grows.

The second barrier is reimbursement complexity for novel modalities. Gene therapy platforms and complement inhibitors carry list prices of USD 50,000–USD 100,000 per treatment course, and payer willingness-to-pay frameworks in Europe's HTA-governed markets — particularly NICE in the UK and IQWiG in Germany — have not kept pace with manufacturer pricing expectations. This is partially cyclical, as reimbursement frameworks adapt over multi-year timeframes, but the risk to early commercial launches is real and immediate. Of these two barriers, the biosimilar structural erosion is more dangerous to the overall growth thesis, because it attacks the revenue base that funds the R&D pipeline sustaining market expansion.

Emerging opportunities in vitreoretinal disorders

The clearest near-term opportunity is geographic atrophy, where Syfovre and Izervay (avacincaptad pegol, Astellas) have established two competing commercial franchises in a disease affecting 5 million Americans and 8 million Europeans with no prior standard of care. The condition required by this opportunity to fully materialise is sustained payer reimbursement coverage — currently pending in several European markets — which will shift treatment from specialist centres to broader retinal practices, multiplying addressable patient reach. Given that geographic atrophy patients are older and more treatment-naive than wet AMD patients, practice adoption curves are steeper and faster than typical ophthalmic launches.

A second opportunity is the expansion of vitreoretinal surgical volumes in emerging markets, specifically India, Brazil, and Southeast Asia, where a rapidly growing cohort of fellowship-trained vitreoretinal surgeons is raising procedural capacity in private hospital networks. Alcon and DORC are already establishing distribution infrastructure in these geographies, but the opportunity for specialised small-gauge vitrectomy consumables remains underserved. The condition required for this to materialise is health insurance expansion — already progressing in India under Ayushman Bharat and in Brazil under Plano de Saúde reforms — which brings surgical retinal procedures within reimbursed coverage for a middle-income patient cohort previously excluded from intervention.

Investment case: Bull, bear, and what decides it

The bull case rests on three simultaneous catalysts: complement inhibition achieving mainstream European reimbursement by 2027, gene therapy approvals from REGENXBIO or Adverum generating new USD 500 million-plus revenue pools before 2030, and continued volume growth from Asia Pacific as diabetes-linked retinopathy drives first-treatment initiations at scale. Under this scenario, the market grows above its base CAGR, pricing power in novel modalities more than offsets biosimilar erosion in legacy anti-VEGF franchises, and surgical device revenues rise in parallel as vitreoretinal procedures increase in absolute number globally. Companies with diversified portfolios across biologics, devices, and pipeline — particularly Novartis and Roche — capture disproportionate share.

The bear case is driven by a convergence of pricing headwinds: European HTA bodies systematically reject complement inhibitor reimbursement bids at current price points, U.S. Medicare drug price negotiation under the Inflation Reduction Act targets Eylea HD as an early negotiation candidate, and gene therapy programs fail in Phase 3 on durability endpoints — the precise weakness that has historically derailed ocular gene therapy. Under this scenario, revenue growth slows to 4–5% annually through 2030, concentrated in surgical devices and diagnostics while therapeutic revenues stagnate. No single next-generation biologic fills the USD 1.8 billion annual gap created by biosimilar erosion, and market consolidation accelerates under margin pressure.

The swing variable is U.S. payer formulary positioning for complement inhibitors in 2026. If Express Scripts and CVS Caremark grant Syfovre and Izervay unrestricted Tier 2 formulary status in their 2026 national formulary negotiations — currently under active review — the geographic atrophy segment becomes the market's primary growth engine and the bull case plays out. If payers impose step edits requiring prior biologic failure or restrict coverage to moderate-to-severe disease only, complement inhibitor penetration stalls at under 15% of the eligible population and the bear case dominates. This single formulary decision, expected Q4 2025, is the most consequential near-term event in this market.

Market at a Glance

Regional performance: Where vitreoretinal disorder treatment is growing fastest

North America remains the largest revenue contributor, accounting for an estimated 47% of global vitreoretinal market revenues in 2024, driven by the highest per-capita anti-VEGF prescription rates globally, premium reimbursement for surgical devices, and the first-mover advantage of complement inhibitor launches. Europe is the second-largest region, with Germany, France, and the UK representing the bulk of therapeutic revenue, though HTA-driven price negotiations continue to suppress net realised prices for novel agents below U.S. levels. Europe's growth rate over the forecast period will be constrained to approximately 5.5% annually unless complement inhibitors clear NICE and IQWiG reimbursement hurdles before 2027.

Asia Pacific holds the highest growth rate among all regions, forecast at 9.8% CAGR through 2034, fuelled by the world's largest diabetic population concentrated in China and India, accelerating healthcare infrastructure investment, and expanding retinal specialist capacity in secondary-tier Chinese cities. China specifically is investing heavily in domestically manufactured anti-VEGF biosimilars — Lucentis biosimilars from Henlius Biotech are already reimbursed under the National Reimbursement Drug List — creating a high-volume, lower-ASP model that prioritises patient reach over premium pricing. Latin America and the Middle East and Africa, while smaller in absolute revenue, are posting above-average growth rates as private ophthalmology networks expand and surgical tourism for complex retinal procedures increases to hub centres in Brazil and the UAE.

Leading Market Participants

• Novartis AG
• Regeneron Pharmaceuticals
• Bayer AG
• Roche (Genentech)
• Apellis Pharmaceuticals
• Astellas Pharma
• Alcon Inc.
• REGENXBIO Inc.
• Bausch + Lomb
• DORC International

Where is vitreoretinal disorder treatment headed by 2034

By 2034, the vitreoretinal disorder market will have undergone a technology layer shift. Anti-VEGF biologics will still constitute the largest single revenue category, but their share of total market revenue will have declined from approximately 58% in 2024 to below 40%, replaced by a more diversified mix of complement inhibitors, gene therapies, TKI-based sustained-release implants, and next-generation surgical systems. The market will be larger but structurally less concentrated around any single mechanism, and per-patient annual treatment costs will bifurcate sharply: high-cost one-time gene therapy interventions versus lower-cost biosimilar anti-VEGF for the broad chronic population.

Among current participants, Novartis is best positioned for 2034 because its portfolio spans Beovu (brolucizumab) in wet AMD, the Susvimo port delivery platform through Genentech, and a deep pipeline in sustained-release formats — providing revenue continuity across both the legacy injection model and the next-generation delivery paradigm. Apellis Pharmaceuticals, if complement inhibitor reimbursement is secured in Europe by 2027, transitions from a single-product story into the dominant force in geographic atrophy globally. Alcon's strength in surgical hardware and the NGENUITY visualization platform makes it structurally defensive regardless of biologic market shifts, as procedural volume in retinal surgery grows with the aging population irrespective of which drugs are injected.

Market Segmentation

By Therapy Type

• Anti-VEGF Biologics
• Complement Inhibitors
• Corticosteroid Implants
• Gene Therapies
• Laser Photocoagulation
• Photodynamic Therapy

By Indication

• Age-Related Macular Degeneration
• Diabetic Retinopathy
• Diabetic Macular Edema
• Geographic Atrophy
• Retinal Vein Occlusion
• Retinal Detachment

By Device and Surgical Equipment

• Vitrectomy Systems
• Intraocular Tamponades
• 3D Visualization Systems
• Retinal Lasers
• Ophthalmic Microscopes

By End User

• Hospital Ophthalmology Departments
• Specialised Retinal Clinics
• Ambulatory Surgery Centres
• Academic Medical Centres

Frequently Asked Questions

Q1. What is the primary driver of the vitreoretinal disorder market through 2034? ▼

The primary driver is the global diabetes epidemic, which directly fuels diabetic retinopathy and diabetic macular edema — the two highest-volume indications in the market. Over 103 million people currently have diabetic retinopathy, and this cohort is expanding faster than existing therapies can fully penetrate it.

Q2. How significantly will anti-VEGF biosimilars disrupt incumbent revenue streams? ▼

Biosimilar anti-VEGF agents from Biocon, Samsung Bioepis, and Coherus BioSciences are projected to erode incumbent net revenues by USD 1.8 billion annually by 2028. Formulary conversion is progressing faster than manufacturers' high-dose or extended-interval reformulations can compensate.

Q3. Which pipeline segment carries the highest commercial upside before 2030? ▼

Geographic atrophy therapeutics carry the highest upside, representing a previously untreated population of 13 million patients across the U.S. and Europe. Commercial penetration of Syfovre and Izervay beyond 20% of eligible patients requires European reimbursement approval, which is the critical near-term milestone.

Q4. Are gene therapies a realistic commercial threat to chronic biologics within the forecast period? ▼

Gene therapies from REGENXBIO and Adverum Biotechnologies will reach early commercial stages before 2030, but their impact within the forecast period is bounded by high list prices and limited payer acceptance. Chronic biologics remain the volume backbone of the market through at least 2032.

Q5. Which region offers the best risk-adjusted growth opportunity for new market entrants? ▼

Asia Pacific — specifically India and Southeast Asia — offers the best risk-adjusted entry point, combining high unmet need, rising retinal surgeon density, and expanding insurance coverage. Entrants with locally manufactured anti-VEGF biosimilars or affordable vitrectomy consumables face the lowest competitive resistance and fastest volume ramp.